Date
- 2026 (8)
- 2025 (65)
- 2024 (100)
- 2023 (82)
- 2022 (65)
- 2021 (120)
- 2020 (152)
- 2019 (52)
- 2018 (54)
- 2017 (50)
- 2016 (4)
- 2015 (37)
- 2014 (22)
- 2013 (25)
- 2012 (13)
- 2011 (51)
- 2010 (45)
- 2009 (32)
- 2008 (27)
- 2007 (17)
- 2006 (21)
- 2005 (51)
- 2004 (12)
- 2003 (10)
- 2002 (10)
- 2001 (6)
- 2000 (5)
- 1999 (5)
- 1998 (9)
- 1997 (3)
- 1991 (3)
Sponsor content
1157 result(s) found, displaying 21 to 30
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ARIPIPRAZOLE SANDOZ DEPOT aripiprazole 400 mg powder and diluent for prolonged release suspension for injection vial kit.
-
Prescription medicine registrationActive ingredients: rivaroxaban.
-
Australian public assessment report (AusPar)Afqlir; Enzeevu (aflibercept) 2 mg is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (wet AMD), CRVO, BRVO, DMEmyopic and CNV.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for FERRIC CARBOXYMALTOSE SANDOZ iron (as ferric carboxymaltose) 1000 mg/20 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for FERRIC CARBOXYMALTOSE SANDOZ iron (as ferric carboxymaltose) 500 mg/10 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for FERRIC CARBOXYMALTOSE SANDOZ iron (as ferric carboxymaltose) 100 mg/2 mL solution for injection vial.
-
Prescription medicine registrationActive ingredients: aripiprazole, aripiprazole monohydrate.
-
Prescription medicine registrationActive ingredients: azelastine hydrochloride, fluticasone propionate.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ENZEEVU aflibercept 40 mg/mL solution for intravitreal injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AFQLIR aflibercept 40 mg/mL solution for intravitreal injection vial with needle.